Table 1.
Study participant demographics and characteristics.
| Non-completers (n=132) | Completers (n=259) | p-value | |||
|---|---|---|---|---|---|
|
| |||||
| n | % | n | % | ||
|
| |||||
| Age in years (mean) | 41.6 | 44.6 | 0.06 | ||
| Gender | |||||
| Female | 53 | 40.2 | 122 | 47.1 | 0.19 |
| Male | 79 | 59.9 | 137 | 52.9 | |
| Treatment regimen | |||||
| Isoniazid and rifapentine | 13 | 9.9 | 74 | 28.6 | <0.001 |
| Rifampin alone | 12 | 9.1 | 70 | 27.0 | |
| Isoniazid alone | 107 | 81.1 | 115 | 44.4 | |
| Type of insurance* | |||||
| Private | 10 | 8.7 | 49 | 23.3 | <0.001 |
| Medicare/Medicaid/government-funded | 30 | 26.1 | 45 | 21.4 | |
| Charity/no insurance | 55 | 47.8 | 107 | 51.0 | |
| Other | 20 | 17.4 | 9 | 4.3 | |
| Race | |||||
| White | 11 | 9.1 | 18 | 7.1 | 0.10 |
| Black | 39 | 32.2 | 55 | 21.6 | |
| Asian | 46 | 38.0 | 115 | 45.1 | |
| Mexican/Other Hispanic | 16 | 13.2 | 32 | 12.6 | |
| Pacific Islander | 5 | 4.1 | 27 | 10.6 | |
| Other | 4 | 3.3 | 8 | 3.1 | |
| Foreign-born | 110 | 90.2 | 230 | 91.3 | 0.73 |
| English-speaking | 66 | 50.8 | 136 | 53.3 | 0.63 |
| Marital status† | |||||
| Married | 48 | 60.8 | 115 | 73.7 | 0.04 |
| Unmarried/separated | 31 | 39.2 | 41 | 26.3 | |
| Homeless†† | 18 | 15.0 | 26 | 10.7 | 0.24 |
| Experienced Side effects | 37 | 28.0 | 94 | 36.3 | 0.10 |
| Number of medical problems | |||||
| 0 | 47 | 35.6 | 130 | 50.2 | 0.01 |
| 1–2 | 42 | 31.8 | 77 | 29.7 | |
| 3+ | 43 | 32.6 | 52 | 20.1 | |
| Number of medications | |||||
| 0–1 | 45 | 34.1 | 93 | 35.9 | 0.86 |
| 2–3 | 49 | 37.1 | 89 | 34.4 | |
| 3+ | 38 | 28.8 | 77 | 29.7 | |
| Tobacco use | 23 | 17.4 | 26 | 10.0 | 0.04 |
| Alcohol use (>3 drinks, abuse, or dependence) | 25 | 18.9 | 27 | 10.4 | 0.02 |
Unless indicated, less than 5% of data was missing
*
16.8% missing data
†
40.0% missing data
††
7.1% missing data